- Intrahealth has integrated HEALWELL AI’s cutting-edge AI-powered physician co-pilot to aid cardiologists in identifying patients at high risk of cardiovascular disease (CVD). This innovation is the result of HEALWELL AI recent acquisition of Intrahealth and is the first of many innovations that will come through for the Profile Electronic Medical Record.
- The new co-pilot will be integrated into Intrahealth’s EMR “Profile” and available for cardiology centers in future releases.
- HEALWELL AI “Co-pilot” is currently being launched across WELL Diagnostic Centres, Canada’s largest cardiology and medical diagnostic group, offering invaluable support to cardiologists at over 40 locations across Ontario.
- Given that cardiovascular disease remains the leading cause of death globally, accounting for approximately 32% of deaths worldwide in 2019, the introduction of this AI co-pilot addresses a critical need for early detection and intervention. Additionally, HEALWELL AI plans to utilize this technology to accelerate life sciences research and development in the field of CVD and generate new business opportunities through its recently acquired Clinical Research Organization (CRO), BioPharma Services Inc.
Vancouver, BC and Toronto, ON, July 22, 2024 – Intrahealth, HEALWELL AI Company. Intrahealth, a subsidiary of HEALWELL AI Inc. (TSX: AIDX), an enterprise class EHR provider supporting care delivery and HEALWELL AI Inc. (TSX: AIDX), a healthcare technology company focused on AI and data science for preventative care, are jointly pleased to announce the launch of an integrated AI-powered co-pilot for cardiologists exclusively powered by HEALWELL AI, aimed at identifying patients at high risk of cardiovascular disease (“CVD”).
Dr. Alexander Dobranowski, CEO of HEALWELL, commented, “The launch of our AI-powered co-pilot for specialists marks a significant milestone in our mission to enhance healthcare through advanced technology. By expanding our AI capabilities to include cardiovascular disease detection, we are equipping cardiologists with enhanced tools and decision support necessary to identify at-risk patients earlier, ultimately improving patient outcomes and reducing healthcare costs. The integration of this tool into Intrahealth’s Profile EHR is particularly important, as it provides Intrahealth customers globally with access to cutting edge innovations. This vast dataset will assist Intrahealth customers and allows us to continuously refine and enhance the co-pilot.”
Dorian Prior, President of Intrahealth said “Intrahealth is committed to leveraging advanced technology to improve healthcare outcomes. Our integration with this leading-edge AI-powered co-pilot represents a significant advancement in this mission. By equipping cardiologists with this innovative tool, we aim to improve diagnostic accuracy and patient outcomes.”
Dr. Paul Kannampuzha, Chief Cardiology Officer of WELL Diagnostic Centres commented. “As a cardiologist, I am encouraged by how AI can help provide improved disease detection and decision support for cardiologists across the country. I believe this technology will help drive improved preventative care and ensure patients don’t fall through the cracks.”
Cardiovascular disease (CVD) is a group of disorders affecting the heart and blood vessels and is the leading cause of death globally, responsible for approximately 32% of deaths worldwide in 2019(1). In Canada, recent estimates suggest that CVD costs about $22 billion per year and is considered the second leading contributor to healthcare costs(2). Identifying patients with worsening cardiovascular conditions earlier is crucial, as cardiovascular disease is the third leading cause of death in Canada.
The global market for pharmaceutical drugs supporting cardiovascular disease was valued at approximately USD 144.1 billion in 2023. It is projected to grow at a compound annual growth rate (CAGR) of approximately 4% over the next decade, reaching an estimated USD 207.8 billion by 2033 (Precedence Research)(3). HEALWELL expects to leverage this technology to help accelerate life sciences research and development opportunities related to CVD and drive new business opportunities for its newly acquired Clinical Research Organization (CRO), BioPharma Services Inc.
Footnotes:
- https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-%28cvds%29
- https://link.springer.com/article/10.1007/s41669-021-00257-8
- https://www.precedenceresearch.com/cardiovascular-drug
About HEALWELL AI
HEALWELL is a healthcare technology company focused on AI and data science for preventative care. Its mission is to improve healthcare and save lives through early identification and detection of disease. Using its own proprietary AI technology and competencies which includes data science, electronic health records and clinical research offerings, the Company is developing and commercializing advanced clinical decision support systems that can help healthcare providers detect rare and chronic diseases, improve efficiency of their practice and ultimately help improve patient health outcomes. HEALWELL is publicly traded on the Toronto Stock Exchange under the symbol “AIDX” and on the OTC Exchange under the symbol “HWAIF”. To learn more about HEALWELL, please visit healwell.ai/.
About Intrahealth
Intrahealth, a subsidiary of HEALWELL AI Inc. (TSX: AIDX), is an enterprise class EHR provider supporting approximately 20,000 providers and the care delivery of tens of millions of patients and clients across Canada, Australia and New Zealand. Intrahealth provides a suite of flexible software solutions to a wide variety of customers including health authorities, hospitals, public health outpatient centres, community health, home care, ambulatory care and diverse health care professionals. Intrahealth’s solution is highly configurable and is ideal for complex health environments. To learn more about Intrahealth, please visit https://intrahealth.com.
